novavax covid - Search News

Order byBest matchMost fresh

Novavax’s COVID vaccine gets FDA approval

Healthy Returns: Novavax scores narrower Covid vaccine approval after delay

Novavax can finally breathe a sigh of relief – at least a small one. The Food and Drug Administration approved the company's Covid-19 vaccine after more than a month of delay b

· 26m · on MSN

WebMD · 6h

FDA Approves Novavax COVID Vaccine With Restricted Use

· 2d · on MSN

After delay, FDA approves Novavax’s Covid-19 vaccine, but only for older people and those at high risk

US FDA advisers to consider if new COVID shots should target LP.8.1 subvariant

The U.S. Senate plans to vote this week to bar California's landmark plan to end the sale of gasoline-only vehicles by 2035 that has been adopted by 11 other states, Majority Leader John Thune said on...

· 2h

· 4h

F.D.A. Poised to Restrict Access to Covid Vaccines

· 5h

Annual COVID-19 Shots For Healthy Younger Adults, Children Will No Longer Be Routinely Approved

FDA to limit future Covid-19 shots to older people and those at risk of serious infection

The change means that Covid-19 boosters will likely be available in the fall for adults ages 65 and older and those with underlying conditions that may put them at higher risk of a Covid-19 infection...

· 5h

· 6h

New Trump vaccine policy limits access to COVID shots

· 3h

FDA sets new COVID booster guidelines for healthy adults under 65

4hon MSN

Who can get updated COVID vaccines this fall? FDA will OK for high-risk groups, calls for new clinical trials

"The FDA will approve vaccines for high-risk persons and, at the same time, demand robust, gold-standard data on persons at low risk," the agency said in an article published by The New England Journal of Medicine, authored by FDA Commissioner Dr. Martin Makary and his new top vaccines official, Dr. Vinay Prasad.

1hon MSN

The FDA is making it more difficult for Americans to get vaccinated for covid

In the NEJM article, the FDA notes that covid booster uptake has been low in the US, with less than a quarter of people getting the shot each year. “There may even be a ripple effect: public trust in vaccination in general has declined,” it says.

BioSpace1h

FDA’s New Risk-Based Approach to COVID-19 Vaccines Aims to Ease ‘Public Distrust’: Makary, Prasad

The new framework was well-received by biopharma analysts, who say it “largely formalizes” current COVID-19 vaccination trends.

Trump administration set to limit COVID-19 shot approvals to the elderly, highest-risk

Top officials in the Trump administration on Tuesday announced they will limit the approval of new COVID-19 vaccines to adults over 65 and people who are high risk. The move is a significant shift

STAT1d

Pharmalittle: We’re reading about Regeneron buying 23andMe, the Novavax Covid shot, and more

The FDA finally approved Novavax's Covid-19 vaccine, but placed restrictions on it that its two competitors in the U.S. do not face